🇺🇸 FDA
Patent

US 9896511

Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

granted A61KA61K2039/505

Quick answer

US patent 9896511 (Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505